http://martinczaikowski.blogspot.com.au/2015/03/miracles-do-happen.html?m=1
So my
So far so good.
Sowing REAL
We listen to others, we get a buzz from others predictions, but the true HEALING comes from knowing your
I SAY "
"PRAY FOR COURAGE AND STRENGTH, GOD WILL DELIVER, AND WHEN YOU FEEL THIS COURAGE, WHEN YOU FEEL THIS STRENGTH. LOOK AROUND AT THIS MAGNIFICENT LIFE AND SAY THANKS. BE GRATEFUL FOR IT ALL, THE CHALLENGES, THE CANCER, THE LONELINESS, THE SEPARATION THAT INEVITABLY COMES"
WE ARE MADE IN GODS IMAGE, WE ARE VERY VERY STRONG AND POWERFUL. WHEN WE DWELL ON OUR FEAR, WE LOOSE OUR POWER. WE NEED ALL OUR POWER AS ILLNESS IS A GREAT CHALLENGE.
I AM NED AGAIN, SO CAN YOU BE.
JOINT THE WINNING TEAM
http://www.mskcc.org/cancer-care/trial/12-224
http://www.onclive.com/conference-coverage/nyl-2013/PD-1-and-PD-L1-Inhibitors-Expected-to-Change-the-Landscape-of-Lung-Cancer-Treatment
Rizvi said that responses continue in 10 of 22 remaining patients. He added that, among patients who discontinued the trial for reasons other than disease progression, six of the remaining seven continued to respond. These results raise questions about how long patients need to take the drug, he said. “If you reset your immune system, if you turn your T cells back on, do you need to keep dosing with this drug?” he asked. “We don’t really know the answer to that.” Additional study participants benefited from nivolumab , but were not included in data as positive responders because their benefit was delayed or they experienced initial inflammation of their tumors that mimicked progression, Rizvi pointed out. About 5% to 10% of patients can be expected to exhibit that reaction, but an indication of eventual outcome is that those who will eventually respond tend to feel better while on nivolumab , he said - See more at: http://www.onclive.com/conference-coverage/nyl-2013/PD-1-and-PD-L1-Inhibitors-Expected-to-Change-the-Landscape-of-Lung-Cancer-Treatment#sthash.j3S9z2vk.dpuf
DO YOU SEE THE POINT HERE, DURABLE ONGOING RESPONSES, SO NOW WE CAN INHIBIT PDL1 AND ADOPT A SENSIBLE WAIT AND SEE. All my nivolumimab test rats to VIP treatment while we watch cytokines and markers for signs of disease progression, now we also address the post nivolumimab inflamation risk agressively . YOU DONT GET THAT ON THESE BULLSHIT CLINICAL TRIALS, they learn while you jump on your sword, stuff that! I arrange treatments, so you live!
Sharing Gods Healing Glory!!!!!!!!!!!!!
I got
QUESTION
How long will it take to salvage a liver that 70%
Pete
I hope you do. I have an absolute soft spot for everyone on this forum, if I can ever help, just ask!